The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Here's why Metallica stopped using guitar amps live, according to James Hetfield's guitar tech. Metallica fans may or may not have even noticed that the rockers don't have a bunch of amps lined up ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

You're back in school and suddenly have to take a test, despite not having been present to learn any of the material. Your teeth are suddenly falling out. You run into an acquaintance you haven't seen ...

When we use words to communicate, we not only have to choose what to say, but also what not to say, and how to say it. How we decide to frame a message can influence how people think, feel, and ...

We know we do it. But have you ever studied a person’s gestures as they spoke to you? Or noticed how you move your hands subconsciously when speaking? Gesturing comes naturally to many of us and is ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In recent years, ChatGPT has exploded in popularity, with nearly 200 million users pumping a total of over a billion prompts into the app every day. These prompts may seem to complete requests out of ...

Dashia is the consumer insights editor for CNET. She specializes in data-driven analysis and news at the intersection of tech, personal finance and consumer sentiment. Dashia investigates economic ...